Table 1 Baseline characteristics in intent-to-treatment population
|  | CEOP/IVE/GDP (N = 51) | CEOP (N = 51) |
|---|---|---|
Age (years; median IQR) | 56 (46.0–64.0) | 60 (52.0–65.0) |
 ≤ 60 years | 33 (65%) | 28 (55%) |
 > 60 years | 18 (35%) | 23 (45%) |
Gender | ||
 Male | 34 (67%) | 32 (63%) |
 Female | 17 (33%) | 19 (37%) |
Ann Arbor Stage | ||
 I–II | 10 (20%) | 9 (18%) |
 III–IV | 41 (80%) | 42 (82%) |
B symptoms | ||
 Absent | 26 (51%) | 23 (45%) |
 Present | 25 (49%) | 28 (55%) |
Performance status | ||
 0–1 | 46 (90%) | 42 (82%) |
 2 | 5 (10%) | 9 (18%) |
Serum LDH | ||
 Normal | 25 (49%) | 28 (55%) |
 Elevated | 26 (51%) | 23 (45%) |
EBV-DNA | ||
 Undetectable | 35/45 (78%) | 30/42 (71%) |
 Detectable | 10/45 (22%) | 12/42 (29%) |
Extra-nodal involvement | ||
 0–1 | 34 (67%) | 30 (59%) |
 ≥ 2 | 17 (33%) | 21 (41%) |
Extra-nodal site | ||
 Skin | 4 (8%) | 5 (10%) |
 Gastrointestinal tract | 5 (10%) | 7 (14%) |
 Liver | 4 (8%) | 2 (4%) |
 Spleen | 14 (27%) | 14 (27%) |
 Lung | 2 (4%) | 3 (6%) |
 Bone marrow | 15 (30%) | 21 (41%) |
 Bone | 5 (10%) | 8 (16%) |
 Breast | 0 | 1 (2%) |
IPI | ||
 0–1 | 14 (27%) | 16 (31%) |
 2–3 | 30 (59%) | 26 (51%) |
 4–5 | 7 (14%) | 9 (18%) |